Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels
- Conditions
- Female Sexual Interest/Arousal Disorder
- Interventions
- Dietary Supplement: LibicareDietary Supplement: active control
- Registration Number
- NCT04188600
- Lead Sponsor
- Procare Health Iberia S.L.
- Brief Summary
The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared with active control.
- Detailed Description
The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared with active control.
Despite current consensus in the literature that Female Sexual Dysfunction can manifest at any age in a woman´s life, researchers as Sarrel documented that during menopause, up to 40% of women are experiencing a decrease in their sexual libido. The common assumption is that the menopause contributes to a drop of the sexual desire probably as a result of low production of hormones from ovaries, at the same time will reduce the estrogen and testosterone. This reduction starts to be reduced in the thirties and continues to reduce progressively at a constant rate reaching of about 50% of their initial highest levels by the time they reach menopause. Other hormones could be involved as Sex hormone-binding globulin (SHBG) or dehydroepiandrosterone (DHEA), both are related with testosterone levels.
Libicare® is a dietary supplement whose ingredients could have positive effects on the improvement of sexual function in women with low desire and arousal levels.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
- Female aged between 40 and 60 years old.
- Healthy peri or postmenopausal women.
- Body Mass Index (BMI) between 18,5-29,9.
- Female with low sexual desire and low arousal with a score ≤26.55 on the questionnaire Female Sexual Function Index (FSFI) .
- Patients who signed the Informed Consent Form.
- Female with uncontrolled thyroid function.
- Female with severe genital pain (vaginism, stopping intercourse because of severe pain).
- Female diagnosed with primary female orgasmic disorder.
- No coital intercourse a month.
- Lack of steady sexual partner.
- Suffering from any serious medical condition (any disease which may force the participant to use drug during the study).
- Suffering from major depression disorder or other psychiatric disorders.
- Women on anticoagulant treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description treatment group Libicare The treatment group will be treated with Libicare for three month (2 tablets/day). After the first three months (12 weeks) of treatment, the treatment group will be classified into two populations: * Responding patients: this population, defined by FSFI score \> 26.55, will be randomized (1:1) into 2 groups: one of them will take Libicare® for further 12 weeks (total period on treatment: 24 weeks) and the other group will remain under observation with no treatment for further 12 weeks (total period on treatment: 12 weeks). * Non-responding patients: this population, defined by FSFI score ≤ 26.55, will intake Libicare® for further 12 weeks (total period on treatment: 24 weeks). active control group active control The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks) active control group Libicare The active control group will be treated with a Selenium and vitamins B complex for three month (2tablets/day). After the first three months (12 weeks) of treatment, patients of the active-control group will cross over the treatment to Libicare® for three months (12 weeks)
- Primary Outcome Measures
Name Time Method Evolution of sexual desire and arousal 12 weeks The evolution of the composite score from sexual desire and arousal obtained using FSFI (Female Sexual Function Index) questionnaire. It has 19 questions with six domains included desire, arousal, lubrication, orgasm, satisfaction and pain, and a general score in which higher scores reflected better sexual activity.
- Secondary Outcome Measures
Name Time Method The improvement of is frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms using the SAL© at 6, 12 and 24 weeks The improvement of is frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms using the SAL© ((Sexual Activity Log©). It is a weekly diary that it measures frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms.
The evolution of other each sexual FSFI domain score at 6, 12 and 24 weeks The evolution of other each sexual FSFI domain score (Female Sexual Function Index) It contains 2 questions of desire domain and 4 questions of arousal domain. Higher scores reflected better sexual activity.
To evaluate the hormonal levels (free testosterone and SHBG) at 6, 12 and 24 weeks changes in hormonals levels
Clinical satisfaction of the women with the treatment, using a Likert-type scale at 6, 12 and 24 weeks Clinical satisfaction of the women with the treatment, using a Likert-type scale of 7 points (from 1 = Very satisfied to 7 = Very dissatisfied)
The evolution of the composite score from sexual desire and arousal at 6 and 24 weeks The evolution of the composite score from sexual desire and arousal obtained using FSFI (Female Sexual Function Index) questionnaire. It has 19 questions with six domains included desire, arousal, lubrication, orgasm, satisfaction and pain, and a general score in which higher scores reflected better sexual activity.
The evolution of the FSFI questionnaire total score at 6, 12 and 24 weeks The evolution of the FSFI (Female Sexual Function Index) questionnaire total score. Composite score from sexual desire and arousal domains will be calculed as the sum of desire items (2 questions) and arousal items (4 questions). Higher scores reflected better sexual activity.
The improvement in the Quality of life of women by EQ-5D-5L questionnaire at 12 and 24 weeks The improvement in the Quality of life of women by EQ-5D-5L (European Quality of Life-5 Dimensions) questionnaire. It comprises the same 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The result is in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Weight, height and BMI at baseline, 6, 12 and 24 weeks Safety endpoint for evaluating weigh and BMI (body mass index) changes.
Adverse events and adverse drug reactions at 6, 12 and 24 weeks. To evaluate the safety of libicare measuring the incidence and duration of adverse events and adverse drug reactions.
The evolution of the vitality status obtained using the Subjective Vitality Scale questionnaire at 12 and 24 weeks The evolution of the vitality scale (an 7-point Likert Scale) contains 7 items. Higher scores reflected better vitality status.
The evaluation of the degree of therapeutic compliance at 6, 12 and 24 weeks The evaluation of the degree of therapeutic compliance throught Likert Scale of 5 points (from 1 = Very satisfied to 5 = Very dissatisfied) will be analysed by means of percentage.
Trial Locations
- Locations (1)
Procare Health Iberia
🇪🇸Castelldefels, Barcelona, Spain